Top Story

Diabetes and the heart: Top news of 2019

January 19, 2020
FDA News

FDA approves CV risk indication for semaglutide

January 17, 2020
The FDA on Thursday approved a new indication for the GLP-1 receptor agonist semaglutide to reduce the risk for major adverse cardiovascular events in adults with type 2…
Meeting NewsPerspective

Dapagliflozin may improve lung fluid volume in HF

January 17, 2020
PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin was not associated with a reduction in mean lung fluid volume among adults with HF with reduced…
In the Journals

REWIND: Dulaglutide reduces stroke risk in type 2 diabetes

January 13, 2020
Middle-aged and older adults with type 2 diabetes and additional cardiovascular risk factors assigned the GLP-1 receptor agonist dulaglutide were 24% less likely to…
More Headlines »

Managing Chronic Heart Failure in Special Populations

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

More »
Meeting News

VIDEO: Heart in Diabetes aims to address ‘avalanche of data’ on diabetes, CVD

July 16, 2019
More »
Meeting News

VIDEO: George Grunberger, MD, highlights AACE diabetes algorithm update

July 14, 2019
More »